Replies to post #135988 on Avid Bioservices Inc (CDMO)

[biopharm]

that was probably not the first thing I thought of when I heard that it was possible that Peregrine could only charge "cost" plus minor other associated costs..etc but it was the second thing I thought of and if Peregrine was forced into this type of situation: why not upgrade completely and to the max to have the best manufacturing facility around and the price they would charge would still be less than what SOC would be... or they make it just so happen to work out that way.

SOC = 100% of current cost...

Peregrine charges 50% of that ? not sure but insurance would gladly pay 50% of SOC than they are generally paying in the past (at least while the drug is on the market for "extended care".., and then once full Approval comes the price can be revised...... but then you work with that number and upgrade accordingly because eventually they will have to anyhow and why not do it if you are placed into the position where you can not profit to the max... but you can certainly "expand" "upgrade" and have a top tier manufacturing facility... so there is plenty of production left for the customers that may call after they finally hear of Avid with maybe a new advertisement? : )

Have to make the best of the situation... and the FDA rules allows for it so now its time for Peregrine to start playing their cards right or they probably always have... and they are certainly not going to tell us.

[entdoc]

most amazing part of PPHM narrative is how the anti-aminophospholipid (anti-PS, Bavituximab) platform is growing, and is not becoming obsolete. When a "discovery" is deemed obvious, and becomes a part of the background, then it is truly revolutionary. Startling is how the heads of the PPHM anti-PS hydra are budding so fast and growing. The platform grows more and more solid. Unfortunately, as I posted almost a decade ago, PPHM stock trades like a public utility. Ironic, huh.